Although high levels of oncogenic expression are an important biomarker in diagnosing HER2-positive breast cancer, our data support the hypothesis that even low levels of HER2 protein expression can be associated with disease aggressiveness, poor patient outcome and therapeutic resistance (Gilcrease et al., 2009). Here, ERBB2 is linked to breast cancer.